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Abstract 
Objective: Our objective was to do an epidemiologic survey of patients with multifocal 
motor neuropathy (MMN) in comparison with those with amyotrophic lateral sclerosis 
(ALS) in Japan.   
Methods: In this retrospective study, we examined 46 patients with MMN and 1,051 
patients with ALS from major neuromuscular centers in Japan from 2005 to 2009.  
Diagnosis was based on the European Federation of Neurological Societies/Peripheral 
Nerve Society (EFNS/PNS) and the revised El Escorial criteria.  The efficacy of 
intravenous immunoglobulin (IVIg) was also taken into consideration in the diagnosis 
of MMN.   
Results: The ratio of MMN to ALS patients (0-0.10) varied among the centers, but 
mostly converged to 0.05.  The prevalence was estimated to be 0.29 MMN patients 
and 6.63 ALS patients per 100,000 population.   
Conclusions: The frequency of MMN patients was around 1 out of 20 ALS patients, 
and MMN was possibly underdiagnosed in some centers. 
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Introduction 
Multifocal motor neuropathy (MMN) is characterized by predominant 
involvement of motor nerves presenting with slowly progressive muscle atrophy and 
weakness, a typical age of onset between the third and fifth decades of life, and a high 
prevalence in men.
1-3
 The characteristic diagnostic features of MMN are conduction 
block (CB) in multiple peripheral nerves and the presence of anti-GM1 IgM 
antibodies
4-7
.  However, the diagnosis of MMN may be missed in those without overt 
evidence of CB or elevated anti-GM1 IgM antibody levels
8-10
.  CB may not be 
detected in MMN patients whose demyelinating lesion is located in proximal nerve 
segments (e.g., plexus, nerve root)
11
 or when it is associated with significant secondary 
axonal loss
8,12
.  Several diagnostic criteria for MMN have been proposed
13-15
.  The 
European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) 
criteria may have limited sensitivity due to the possibility of undetected CB 
11, 13, 16
.  
MMN is treatable with various immunomodulatory therapies, particularly intravenous 
immunoglobulin (IVIg), and the response may be a feature that distinguishes MMN 
from lower motor neuron diseases, including amyotrophic lateral sclerosis (ALS)
17, 18
.   
 Except for 1 clinic-based study that estimated the prevalence of MMN to be 
approximately 10% of that of ALS
19
, detailed large-scale epidemiological studies of 
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MMN have been undertaken rarely.  The lack of knowledge of the above technical 
limitations in the diagnosis of MMN, and the rarity of the disease, might lead clinicians 
to underdiagnose MMN.  We therefore conducted an epidemiological survey of MMN 
in major neuromuscular centers in Japan and compared it with ALS, whose prevalence 
is known.   
A brief preliminary report of this study has been published in Japanese
20
. 
Methods 
Patients.  This study was based on a retrospective hospital-based survey in Japan.  
The diagnosis of MMN was based on the 2006 EFNS/PNS criteria and the response to 
IVIg.  The 2006 criteria were used, because the latest criteria were not available at the 
time of clinical evaluation.  We excluded patients with MMN who died during the 
course of the study because one of those patients might actually have had ALS.  The 
diagnosis of ALS was made by using the revised El Escorial criteria, and patients who 
fulfilled the “clinically definite,” “clinically probable,” or “laboratory-supported 
probable” criteria were included for further epidemiological analysis21.  We excluded 
those with the “possible” criterion, because it might include MMN and other 
neuromuscular conditions.  First, we sent questionnaires to 46 major neuromuscular 
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centers in Japan requesting clinical information on patients with MMN and ALS at each 
site.  Twenty-five centers (54.3%) expressed their willingness to cooperate in the 
survey, but 5 centers did not follow through.  Of the 20 centers that responded to the 
second survey, 1 was excluded because of insufficient data for analysis.  We further 
analyzed the clinical records of patients with MMN and ALS from 2005 to 2009.  We 
also checked the results of electrophysiological studies for MMN.  The participating 
19 centers were not biased geographically and were located throughout Japan.   
Electrophysiological study.  Electrophysiological studies were performed at each 
center using conventional techniques.  CB was defined as a >50% reduction in 
compound muscle action potential (CMAP) amplitude/area from distal to proximal 
stimulation (i.e., median, ulnar, radial, and deep fibular nerves)
14, 22
.  Other 
electrophysiological features of peripheral nerve demyelination included reduced motor 
conduction velocity (motor conduction velocity; <75% of the lower limit of normal), 
prolonged distal motor latency, or prolonged minimal F-wave latency (>130% of the 
upper limit of normal), and activity-dependent conduction block (ADCB).
9, 22, 23
 To 
detect ADCB, CMAPs from the abductor pollicis brevis (APB) were determined with 
magnetic stimulation of low-cervical nerve roots.  One-minute voluntary maximal 
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exercise of the APB was performed, and CMAPs were compared before and after 
exercise.  ADCB was defined by a >50% drop in the CMAP amplitude after exercise.
9
   
Epidemiological study.  The Japanese Ministry of Health, Labour, and Welfare has a 
nationwide registry system for ALS patients, and the number of patients registered in 
2009 was 8,492.  First, we calculated the ratio of MMN to ALS patients in each center 
and in the whole study cohort.  The number of patients with MMN in 2009 was then 
estimated based on the ratio of MMN to ALS patients.  The population of Japan was 
based on data from the national population census in 2009.  We estimated the 
prevalence of MMN and ALS (number of cases/100,000 persons), and the 95% 
confidence interval (CI) in 2009 by assuming a binomial distribution.  The number of 
patients with MMN in Japan (Z) was estimated by X*Y/Ny, where X denotes the total 
number of patients with ALS in Japan, and Y and Ny denote the number of patients 
with MMN and ALS, respectively, registered at 19 neuromuscular centers.  The 
variance of Z (Vz) was estimated by the following equation, assuming that X and Y are 
independent: Vz = [E(Y)*E(Y)*Vx + E(X)*E(X)*Vy + Vx*Vy) / (Ny*Ny)], where E(X) 
and E(Y) denote the expected value (mean) of X and Y, respectively, and Vx and Vy 
denote the variance of X and Y, respectively. 
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We conducted the McNemar test to determine whether the prevalence differed 
significantly between MMN and ALS.  Two epidemiologists (SH and KA) conducted 
the overall analysis.   
Clinical characteristics of MMN and ALS.  Basic data, such as gender, age of onset, 
and diagnosis, were collected from patients with MMN and ALS.   
Standard protocol approval, registration, and patient consent.  All investigations were 
approved by the institutional ethics committee of the University of Tokushima.   
Statistical analysis.  The acquired data were processed and analyzed using SPSS 
software (version 11.0, SPSS Inc., Chicago).  Differences in patient characteristics 
between MMN and ALS were tested using the Mann-Whitney U test.  Two-tailed P 
values <0.05 were considered significant.   
Results 
Forty-six patients with MMN and 1,051 patients with ALS were analyzed 
(Table 1).  The onset age of MMN was younger (mean, 42.5 ± 15.0 years; range, 16-74 
years) than that of ALS (mean, 62.2 ± 36.5 years; range, 33-87 years) (P<0.001, Table 1, 
Figure 1).  There was no significant difference in the male:female ratio between MMN 
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(71.7%) and ALS (60.4%) (P=0.12).   
 The ratio of MMN to ALS patients (range: 0-0.10; average: 0.044) varied 
among centers (Table 2, Figure 2).  There were no MMN patients in 3 centers in the 
past 5 years (centers A-C).  On the other hand, 4 centers showed ratios of 
approximately 0.10.  These centers were not close geographically (centers P-S) and 
were staffed by board-certified electromyographers with more than 10 years’ experience 
in nerve conduction studies.  Some centers had a large number of ALS patients 
compared to the number of MMN patients (e.g., centers D, E, and M).  The number of 
ALS patients in the national registry in 2009 was 8,492.  Based on the ratio of MMN 
to ALS patients reported in the whole survey (0.044), the number of MMN patients in 
Japan was estimated to be 372 (95% CI = 266-477).  Overall, the prevalence of MMN 
in Japan was estimated to be 0.29 patients per 100,000 population (95% CI = 0.21-0.37), 
whereas that of ALS was 6.63 patients per 100,000 population (95% CI = 6.49-6.77) 
(P<0.001). 
Discussion 
We conducted an epidemiological survey of patients from multiple 
neuromuscular centers throughout Japan.  The estimated prevalence of MMN in Japan 
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was 0.29 patients per 100,000 population or approximately 1/20 that of ALS.  The 
gender distribution was similar to that reported previously
19, 24
.  The mean age of onset 
of MMN was slightly older than that of a previous study
19
.  The prevalence in our 
study was lower than those in prior studies conducted in Europe.
19, 25
 One clinic-based 
study in Italy estimated the prevalence of MMN to be approximately 10% that of ALS
19
.  
A study in the Netherlands reported the prevalence of MMN to be 0.6 patients per 
100,000 population.
25
 The exact reason for the difference is unknown.  Given the 
similar prevalence of ALS worldwide, a possibility why MMN is less common in Japan 
would be that it is underdiagnosed, particularly in the centers that showed very low 
prevalence.  Another possibility is that the patients visiting neuromuscular centers 
were skewed to the elderly population in Japan, and this might have contributed to the 
lower estimate of MMN than that of ALS.  We compared the ratios of MMN to ALS 
patients among the centers and found considerable variation (0-0.10).  The ratios were 
around 0.10 in the top 4 centers that were widely distributed in Japan and staffed by 
electromyography experts.  It is therefore unlikely that the prevalence of MMN is 
higher in some parts of Japan that it is in others.  Interestingly, 2 of the top 4 centers 
adopted activity-dependent CB as a criterion for diagnosis of proximal CB.  Although 
activity-dependent CB was not widely performed and might not be observed in some 
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patients with MMN,
26
 it appeared to increase the diagnostic sensitivity in this study.   
Our study has a few limitations.  One of the reasons why some cases of MMN 
were underdiagnosed is that MMN was often misdiagnosed as other motor neuron 
diseases, such as ALS.  Another reason is that only 19 of the 46 centers provided data 
for the study.  The 46 centers include various neurological facilities that treat 
neurologic subspecialty or general neurological ones.  The low response rate means 
that we did not intentionally select neurological centers in the first survey.  Further 
diagnostic tests, such as imaging, would further increase the prevalence of MMN, and 
such efforts would enable us to provide the appropriate immunological treatment.  
Although MMN is considered to be rare, its accurate diagnosis should rely heavily on 
clinical suspicion and electrodiagnostic investigations.  
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Abbreviations: 
ADCB: activity-dependent conduction block  
ALS: amyotrophic lateral sclerosis 
APB: abductor pollicis brevis 
CB: conduction block  
CI: confidence interval   
CMAP: compound muscle action potential  
EFNS/PNS: European Federation of Neurological Societies/Peripheral Nerve Society 
IVIg: intravenous immunoglobulin 
MMN: multifocal motor neuropathy  
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Figure Legends 
Figure 1. Distribution of age of onset. Proportion is defined by the ratio of the number 
of patients according to age of onset to the total number of MMN or ALS patients.  
MMN, multifocal motor neuropathy; ALS, amyotrophic lateral sclerosis. 
Figure 2. Geographical distribution of the ratios of MMN to ALS patients among 
centers. Crosses: non-participating centers; triangle: center that provided inappropriate 
data; squares: participating centers (open squares: 0; gray squares: 0.019-0.081; black 
squares: 0.085-0.10). Open circles indicate the highly-populated cities 
(government-ordinance-designated cities with populations exceeding 0.7 million).   
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Table 1. Demographic data of registered patients 
 
Characteristic MMN (n=46) ALS (n=1051) P value 
Onset age, range (mean±SD), y 16-74 (42.5±15.0) 33-87 (62.2±36.5) <0.001 
Proportion of men (%) 71.7 60.4 0.12 
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Table 2. Ratios and estimated numbers of patients. 
Center           MMN            ALS   Ratio  
 n [
a
age, proportion of men 
(%)] 
n [
a
age, proportion of men 
(%)] 
MMN/ALS 
A 0 58 (60.0±13.6, 53.4) 0 
B 0 26 (68.2±7.2, 53.8) 0 
C 0 26 (60.9±12.0, 61.5) 0 
D 3 (41.3±7.59, 66.7) 154 (62.8±1.10, 62.3) 0.019 
E 2 (57.0±16.0, 50.0) 101 (56.5±12.6, 62.3) 0.020 
F 1 (24.0, 100) 43 (63.5±9.41, 60.5) 0.023 
G 1 (30.0, 100) 34 (63.2±13.4, 50) 0.029 
H 2 (42.0±1.00, 50.0) 58 (62.5±9.40, 41.4) 0.034 
I 1 (62.0, 100) 28 (60.5±11.0, 64.3) 0.036 
J 1 (23.0, 100) 28 (59.2±12.2, 46.4) 0.036 
K 4 (43.0±17.0, 75.0) 94 (64.6±9.42, 54.3) 0.043 
L 1 (37.0, 100) 18 (56.2±12.1, 38.9) 0.056 
M 2 (45.5±0.50, 50.0) 36 (64.3±9.67, 66.7) 0.056 
N 7 (36.0±15.3, 71.4) 113 (64.1±10.4, 58.4) 0.062 
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O 3 (38.0±8.52, 100) 37 (58.8±12.9, 73.0) 0.081 
P 3 (51.3±16.4, 33.3) 35 (63.9±11.6, 65.7) 0.086 
Q 9 (42.8±16.3, 77.8) 99 (61.0±11.4, 57.6) 0.091 
R 4 (55.3±8.93, 75.0) 43 (67.8±10.6, 33.0) 0.093 
S 2 (34.0±17.0, 100) 20 (67.6±8.74, 50.0) 0.10 
b
total 46 1,051 0.044 
Japan 
c
372 
d
8,492 0.044 
 
a
age range: range of onset age (mean±SD).  
b
total: the total number of patients in the 19 centers (A-S). 
c
Number of MMN patients in Japan was estimated on the basis of the number of ALS 
patients (8,492) and the ratio (0.044). 
d
Number of ALS patients was obtained from the national registry in 2009. 
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Figure 1.  
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Figure 2.  
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